Increased expression of the 5-lipoxygenase pathway and its cellular localization in Barrett's adenocarcinoma

Histopathology

Volumn 61, Issue 3, 2012, Pages 509-517

  Boger, Philip C ^a   Shutt, James D ^a   Neale, James R ^a   Wilson, Susan J ^b   Bateman, Adrian C ^a   Holloway, John W ^b   Patel, Praful ^a   Sampson, Anthony P ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Arachidonate 5 lipoxygenase; Barrett oesophagus; Leukotrienes; Oesophageal neoplasms

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; LEUKOTRIENE A4; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE C4 SYNTHASE;

ARTICLE; BIOSYNTHESIS; CANCER DIAGNOSIS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLINICAL EVALUATION; CORRELATIONAL STUDY; DISEASE COURSE; EPITHELIUM CELL; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PATHOLOGIST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SQUAMOUS CELL METAPLASIA; TISSUE SECTION; UPREGULATION;

ADENOCARCINOMA; ARACHIDONATE 5-LIPOXYGENASE; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; PRECANCEROUS CONDITIONS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84865399705     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04258.x     Document Type: Article

References (45)

1. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265; 1287-1289.
2. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. Survival of cancer patients diagnosed in 1995-1999: results and commentary. Eur. J. Cancer 2009; 45; 931-991.
3. Rachet B, Maringe C, Nur U et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol. 2009; 10; 351-369.
4. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am. J. Gastroenterol. 1999; 94; 2043-2053.
5. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat. Rev. Cancer 2003; 3; 676-684.
6. Corder AP, Jones RH, Sadler GH, Daniels P, Johnson CD. Heartburn, oesophagitis and Barrett's oesophagus in self-medicating patients in general practice. Br. J. Clin. Pract. 1996; 50; 245-248.
7. Csendes A, Smok G, Burdiles P et al. Prevalence of Barrett's esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. Dis. Esophagus 2000; 13; 5-11.
8. Ronkainen J, Aro P, Storskrubb T et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005; 129; 1825-1831.
9. Jankowski JA, Anderson M. Management of oesophageal adenocarcinoma-control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus. Aliment. Pharmacol. Ther. 2004; 20(Suppl. 5); 71-80.
10. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420; 860-867.
11. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem. Pharmacol. 2006; 72; 1605-1621.
12. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol. Cancer Res. 2006; 4; 221-233.
13. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294; 1871-1875.
14. Peters-Golden M, Henderson WR. Leukotrienes. N. Engl. J. Med. 2007; 357; 1841-1854.
15. 4 receptors. Prostaglandins Leukot. Essent. Fatty Acids 2003; 69; 123-134.
16. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J. Immunol. 2004; 173; 1503-1510.
17. Hebert MJ, Takano T, Holthofer H, Brady HR. Sequential morphologic events during apoptosis of human neutrophils. Modulation by lipoxygenase-derived eicosanoids. J. Immunol. 1996; 157; 3105-3115.
18. Mellor EA, Austen KF, Boyce JA. Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J. Exp. Med. 2002; 195; 583-592.
19. Ye YN, Liu ESL, Shin VY, Wu WKK, Cho CH. Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. Toxicology 2004; 203; 179-188.
20. Hoque A, Lippman SM, Wu TT et al. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 2005; 26; 785-791.
21. Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J. 2003; 17; 1986-1995.
22. Triadafilopoulos G, Kaczynska M, Iwane M. Esophageal mucosal eicosanoids in gastroesophageal reflux disease and Barrett's esophagus. Am. J. Gastroenterol. 1996; 91; 65-74.
23. 4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. J. Natl Cancer Inst. 2003; 95; 1053-1061.
24. Chen X, Wang S, Wu N et al. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin. Cancer Res. 2004; 10; 6703-6709.
25. Britten KM, Howarth PH, Roche WR. Immunohistochemistry on resin sections: a comparison of resin embedding techniques for small mucosal biopsies. Biotech. Histochem. 1993; 68; 271-280.
26. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 1981; 29; 577-580.
27. Buchwalow IB, Böcker W. Immunohistochemistry: basics and methods. Heidelberg: Springer, 2010; 41-46.
28. 4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J. Clin. Invest. 1998; 101; 834-846.
29. Puddicombe SM, Polosa R, Richter A et al. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J. 2000; 14; 1362-1374.
30. Dixon RA, Diehl RE, Opas E et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990; 343; 282-284.
31. Ferguson AD, McKeever BM, Xu S et al. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 2007; 317; 510-512.
32. Peddareddigari VG, Wang D, Dubois RN. The tumor microenvironment in colorectal carcinogenesis. Cancer Microenviron. 2010; 3; 149-166.
33. Tazzyman S, Lewis CE, Murdoch C. Neutrophils: key mediators of tumour angiogenesis. Int. J. Exp. Pathol. 2009; 90; 222-231.
34. Avis I, Hong SH, Martinez A et al. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J. 2001; 15; 2007-2009.
35. Ohd JF, Wikstrom K, Sjolander A. Leukotrienes induce cell-survival signaling in intestinal epithelial cells. Gastroenterology 2000; 119; 1007-1018.
36. Ago H, Kanaoka Y, Irikura D et al. Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis. Nature 2007; 448; 609-612.
37. 12 receptor. J. Exp. Med. 2009; 206; 2543-2555.
38. 4. Clin. Exp. Allergy 2007; 37; 880-892.
39. Fabre JE, Goulet JL, Riche E et al. Transcellular biosynthesis contributes to the production of leukotrienes during inflammatory responses invivo. J. Clin. Invest. 2002; 109; 1373-1380.
40. Fitzgerald RC, Abdalla S, Onwuegbusi BA et al. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 2002; 51; 316-322.
41. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 2000; 60; 5767-5772.
42. Buttar NS, Wang KK, Leontovich O et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002; 122; 1101-1112.
43. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: exvivo induction by bile salts and acid exposure. Gastroenterology 2000; 118; 487-496.
44. 2 release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent. Am. J. Physiol. Gastrointest. Liver Physiol. 2002; 283; G327-G334.
45. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res. 2001; 61; 6307-6312.